Vaccines have been used successfully for disease elimination programs in many countries. Evidence on the impact of vaccination programs can support decision-making among medical practitioners and policy makers to improve immunization rates. We estimated the health and economic impact of measles vaccination for each of the 48 contiguous states and the District of Columbia since 1964.
state with the average of counts for the preceding and following weeks for which data were available (linear imputation). Our imputed Project Tycho counts likely overestimated CDC data in the vaccination period and would lead to conservative estimates of vaccine impact.
We collected the annual number of measles deaths from the National Vital Statistics System (NVSS) for 1961-2014 and from US vital mortality statistics reports [12] for 1931-1960. We used national-level cost data for all-cause and measles-specific hospitalization in 1995 [2] and state-specific cost data for all-cause hospitalization between 1969 and 2014 [13, 14] to estimate the direct health care costs of measles disease. We used the health care inflation rate to impute missing cost data between 1931 and 2014. We assumed a higher cost of measles hospitalization and measles-related encephalitis compared with nonhospitalized measles. We used the probability of measles hospitalization as reported by CDC surveillance [15] and the probability of measles-related encephalitis from Zhou et al. [2] . We used state-specific annual income data between 1931 and 2014, as reported by the Bureau of Economic Analysis [16] , to estimate indirect costs of measles.
Nationwide coverage data for the measles, mumps, rubella (MMR) vaccine were available for all years between 1931 and 2014, except between 1986 and 1990 (these missing data years were imputed using linear interpolation) [17] . State-specific vaccination coverage rates for 1 dose of the MMR vaccine were available from the National Immunization Survey (NIS) for the years between 1995 and 2014 [18] . In the absence of 2-dose coverage data from NIS, we assumed that 1-dose coverage reported in the NIS was similar to 2-dose coverage. We used the ratio of national and state-specific vaccination coverage rates during the years for which both were available to estimate state-specific vaccination coverage rates for the years 1964-1994 ( Supplementary Figure 1) . We used the cost per vaccination dose for commercial entities to estimate the cost of vaccination ( Supplementary Table 1 ). In the absence of more detailed information, we assumed that commercial vaccine prices would be representative of the cost of vaccines and also of vaccine delivery in the United States, given that most US vaccines are purchased at discounted prices. Previous studies also used commercial pricing to represent the cost of vaccination [19] [20] [21] . We provide additional details about the study methodology in Supplementary Text.
Estimation of Counterfactual Cases
We used a time-series autoregressive integrated moving average (ARIMA) model to estimate the counterfactual number of cases and deaths that would have occurred in the absence of vaccination between 1964 and 2014. We separately estimated counterfactual cases and deaths. ARIMA models represent autocorrelation, seasonal patterns, and trends over time and have been used previously to model infectious disease time-series data [22] . Previous studies have used prevaccination data to estimate counterfactual case counts during the vaccination period using a variety of counterfactual models [1, 22, 23] . A vaccine impact model based on prevaccination data compares a population with a vaccination program (vaccination period) with a population without a vaccination program (prevaccination period), and thus estimates an overall impact of the vaccine that includes the direct and indirect (ie, herd immunity) effects of the vaccine [24] .
For each state, we fitted 72 different ARIMA models to the first 20 years of the prevaccination data using time as the independent variable and measles incidence rates as the dependent variable (1931) (1932) (1933) (1934) (1935) (1936) (1937) (1938) (1939) (1940) (1941) (1942) (1943) (1944) (1945) (1946) (1947) (1948) (1949) (1950) . We used each model to predict (out of sample) the last 10 years of the prevaccination data (1951) (1952) (1953) (1954) (1955) (1956) (1957) (1958) (1959) (1960) using time as the independent variable. The 72 ARIMA models comprised every combination of: (1) 6 specifications of the autoregressive component (0-5), (2) 2 specifications of the difference component (0-1), and (3) 6 specifications of the moving average component (0-5). We defined the best model for each state as the model with the lowest mean squared error between the observed and predicted values for the 1951-1960 testing period (Supplementary Table 2 and Supplementary Figures 2  and 3 ). We then fitted the best model for each state to data from the entire prevaccination period ) and predicted the counterfactual case incidence or death rates. We used the lower and upper bounds of the ARIMA 80% confidence interval as the lower and upper uncertainty bounds for counterfactual estimates ( Supplementary Figures 4 and 5 ). The ARIMA confidence interval became wider over time as predictions for years far from the prevaccination period were less certain vs years shortly after the prevaccination period.
The ARIMA model for deaths in South Dakota did not converge due to an extreme observation of 120 deaths in 1934, compared with an average of 6 deaths in other years. Instead of ARIMA predictions, we used the mean prevaccination measles mortality rate and its 95% confidence interval as the counterfactual estimate for South Dakota.
Costs of Measles Disease
We used nationwide cost data for 2 types of measles-specific hospitalization: (1) nonencephalitis measles (NEM), that is, uncomplicated measles or measles with diarrhea; and (2) measles encephalitis (EM). We used national cost data available for 1995 to compute the proportion of all-cause hospitalization costs that was spent on each type of measles. We then multiplied these proportions by the all-cause hospitalization costs for each state and year to estimate annual state-level hospitalization costs for each type of measles (Supplementary Figure 6) .
We computed the cost related to NEM hospitalizations for each state by multiplying the annual number of measles cases by the probability and cost of NEM. We did the same for EM hospitalizations. We added the costs of NEM and EM hospitalizations to obtain the total direct costs related to measles hospitalization.
We estimated indirect costs related to measles using the human capital approach [25] . We assumed that 1 caregiver would be unable to work for the duration of the average hospitalization period for NEM and EM [2] . We computed the average hourly and daily income per state from annual income information (Supplementary Figure 7) [26], assuming 8-hour work days and 40-hour work weeks. We then multiplied each measles case by the average number of days hospitalized and by the average daily income (Supplementary Text).
We estimated the average direct and indirect cost of a measles case per state and year based on 1000 Monte Carlo simulations of the annual direct and indirect costs of measles, per state, using a gamma distribution. We then multiplied the Monte Carlo cost averages with ARIMA counterfactual case projections to obtain the total direct and indirect cost per state and year. We multiplied the Monte Carlo cost average with the ARIMA counterfactual 80% uncertainty bounds to represent uncertainty bounds of cost estimates. We defined total societal costs related to measles as the sum of direct and indirect costs. We estimated the costs of measles for both the observed and counterfactual scenarios.
Costs of the Measles Vaccination Program
The US immunization program included 2 doses of the measles-containing vaccine from 1989 onwards. We assumed that vaccination coverage represented a 1-dose vaccination schedule between 1964 and 1989 and a 2-dose vaccination schedule after 1989. We estimated the costs of the vaccination program per state and year by multiplying the number of births by the vaccination coverage and the vaccine price per dose (Supplementary Text).
Health and Economic and Impact of Measles Vaccination
We estimated the epidemiological impact of measles vaccination by subtracting the estimated number of counterfactual cases or deaths from the observed number. We calculated the costs prevented by subtracting the total societal costs of observed measles during the vaccination period and the costs of the vaccination program from the total societal costs of counterfactual cases. We reported all costs in this study in 2014 dollars. We stratified our impact estimates by phase of the vaccination period: (1) the vaccine introduction phase, (2) the 1-dose phase (starting when coverage reached 60% in 1971), and (3) the 2-dose phase (starting with introduction of the second dose in 1990).
We computed the nationwide health and economic impact of vaccination as the sum of all state-level cases, deaths, and costs prevented.
We used the Wilcoxon rank-sum test to estimate the association between the number of cases and costs prevented and state-level income, and between vaccination coverage and statelevel income.
Sensitivity Analysis
We estimated the impact of measles vaccination for 8 additional scenarios, each using a different imputation method for missing data (substitution with 0s, substitution with a random count of the same week in a different year), and a different model for estimating counterfactual measles cases or measles-related deaths (linear model, prevaccination mean rates) (Supplementary Figure 8 ). 
RESULTS
Since 1964, 149.4 million (M) children have been vaccinated against measles in the United States at a cost of $12.2 billion, preventing 29.8M cases and 32 000 deaths and saving $25.8 billion in societal costs (Table 1) .
Nationwide Impact
The national average prevaccination measles incidence rate (IR) was 344 cases/100 000 (Table 1, Figure 1 ). During the vaccine introduction phase, the annual IR dropped by 76% to 83/100 000, and by a further 99% to 0.6/100 000 during the 2-dose phase. Before vaccination, the national measles-related mortality rate (mMR) was 0.93 deaths/100 000, representing an average of 1379 deaths per year ( Table 1 ). In the 6 years following vaccine introduction, the mMR dropped by 91% to 0.09 deaths/100 000. In the 25 years between 1989 and 2014 (2-dose vaccination phase), only 4 measles-related deaths were reported, on average, per year for the entire United States.
We estimated that $0.6 billion was invested in measles vaccination during the vaccine introduction phase, when 12.7M children were vaccinated; $2.1 billion was invested during the 1-dose phase (45.1M children vaccinated), and $9.5 billion during the 2-dose phase (91.5M vaccinated) ( Table 1) .
Measles vaccination saved $0.72 per person in the entire population of the United States during the vaccine introduction period. As vaccination coverage improved, cost savings more than doubled during the 1-dose period to $1.71 per person, and tripled to $2.44 per person during the 2-dose period ( (Table 2 ; Supplementary Table 4 ). California prevented the most cases of all states (4.6M), followed by Texas (2.1M) and New York (2.0M).
Measles death rate, observed
After adjustment for population size, states in the West and Northeast prevented 329 and 257 cases/100 000, respectively, compared with lower rates in the Midwest and the South, with 236 and 159 cases prevented per 100 000, respectively (Figure 2) . Wisconsin prevented the most cases per 100 000 (745), followed by Vermont (670.4/100 000) ( Figure 2 ). Mississippi was the only state where our models indicated an increase in cases (2/100 000), but only during the introduction phase of the vaccination period (Figure 3 ). This estimated increase was likely due to underreporting of cases before vaccination (45/100 000 vs 344/100 000 nationally). Underreported prevaccination case counts led to a low number of counterfactual cases and an underestimated impact during the vaccine introduction phase. During the 1-and 2-dose phases, vaccination prevented cases in all states, including 2 and 8 cases/100 000, respectively, in Mississippi (Figure 3 ). We estimated that vaccination prevented 10 551 measles-related deaths in the South, 9364 in the Northeast, 6823 in the West, and 4855 in the Northeast (Table 2 ; Supplementary Table 5 ).
Uncertainty bounds for the number of deaths prevented are wide due to variability in prevaccine count values and uncertainty in ARIMA counterfactual predictions. After adjusting for population size, Northeastern states prevented the most deaths (0.36/100 000), followed by the West (0.26/100 000), the South (0.24/100 000), and the Midwest (0.16/100 000). Interestingly, a Midwestern state (North Dakota) prevented the most deaths per capita with 0.92/100 000, followed by Montana with 0.86/100 000 ( Figure 2) . Our models predicted a minor increase in measles-related mortality for Arkansas (0.013/100 000), Delaware (0.002/100 000), New Mexico (0.019/100 000), Oklahoma (0.009/100 000), Pennsylvania (0.008/100 000), and Texas (0.011/100 000). For these states, our ARIMA model predicted close to 0 counterfactual deaths after vaccine introduction based on already low mortality in the prevaccine period. Outbreaks continued to occur in the early years of the vaccination period, and deaths that occurred in these years exceeded the very low counterfactual mortality.
Between 1964 and 2014, Southern states invested the most in measles vaccination, $4.4 billion, followed by the West ($2.8 billion), the Midwest ($2.8 billion), and the Northeast ($2.2 billion) ( Table 3 ; Supplementary Table 6 ). The largest cost savings due to vaccination occurred in Western states, with a total of $8.5 billion saved in total societal cost. After adjusting for population size, Western states invested the most in vaccination with $1.06 per person, followed by Southern states with $0.99 per person. Utah invested the (Figure 2 ). The largest cost savings occurred in states that prevented the most cases, that is, Wisconsin ($8.81 per person) and Vermont ($7.72 per person). Four states prevented measles cases but not costs (Georgia, Louisiana, North Carolina, and South Dakota). We estimated that these states prevented between 8.1 (North Carolina) and 1.7 (Georgia) cases/100 000 at a cost ranging from $0.27 (Arkansas) to $0.96 per person (North Carolina) ( Figure 2) .
We found substantial differences in the health and economic impact of measles vaccination among states. The difference in impact was associated with income. During the 2-dose phase, states with a per-capita income above the national level prevented 12% more cases (95% confidence interval [CI], 11%-12%), 43% more deaths (95% CI, 40%-43%), and 28% more costs (95% CI, 28%-28%) vs low-income states. A higher impact in high-income states is likely due to stronger vaccination programs: High-income states had 0.5% higher vaccine coverage vs low-income states (95% CI, 0.1%-1.7%).
Sensitivity Analyses
We conducted a sensitivity analysis to compare estimates for cases and costs prevented using different counterfactual models and different imputation methods for missing data (Figure 4 ; Supplementary Figure 8 ). The lowest number of cases prevented (21.7M) and the lowest cost savings ($15.5 billion) resulted from imputing missing data with 0s and using the mean prevaccine IR as counterfactual. The highest number of cases prevented (43.9M) and largest cost savings ($43.9 billion) resulted from imputing missing data with linear interpolation and using the mean prevaccine IR as counterfactual.
DISCUSSION
We found substantial heterogeneity in vaccine impact between states. We found that high-income states prevented more measles cases and deaths and more measles-related costs compared with states with lower income. States with higher incomes would also have higher cost savings, all else being equal, as high-income households would lose more income when a parent stayed home with a sick child. We found substantial variation in the average cost of all-cause hospitalization between states, We did not, however, find a statistically significant association between hospitalization cost and income for states between 1964 and 2014, meaning that differences in hospitalization cost would not explain the heterogeneity of vaccine impact between states. Higher income may explain a higher economic impact of vaccination in high-income states but would not explain the higher number of cases and deaths prevented. We found that high-income states also had higher vaccination coverage compared with low-income states (in the 2-dose phase for which state-level vaccination data were available), suggesting a more effective vaccination program in such states. Other factors could also explain heterogeneity in impact between states, such as population density, level of urbanization, and improved clinical treatment. Indeed, the number of cases prevented did not follow the same pattern as the number of deaths prevented among states due to differences in the prevaccination measles case fatality rate (CFR) among states. The prevaccine CFR ranged from an average low of 0.06% in Wisconsin to a high of 3.66% in Mississippi ( Supplementary  Figure 9 ). Differences in CFRs can be caused by a variety of factors, including heterogeneity in access to health care between states and heterogeneity in the decline of measles mortality before vaccination due to improvements in nutrition, housing, sanitation, and other factors [23, 27] . Previous studies at the national level have estimated that measles vaccination in the United States has saved $8-$11 billion and has prevented 0.5-3.8 million cases per year [2] [3] [4] [28] [29] [30] [31] . Many studies have estimated counterfactual cases based on the average IR during the prevaccination period, and some have used an expansion factor to account for underreporting. Limited historical data about underreporting at the state level have prevented us from using an expansion factor, leading to more conservative estimates by our study.
Our study had several limitations. A lack of impact was most likely due to underreporting of measles IRs before vaccine introduction and to uncertainty in the ARIMA model fit. For example, the reported prevaccination IR in Mississippi was 87% lower (44/100 000) compared with the national average of 344/100 000. When we substituted prevaccine measles IRs for states with IRs below the fifth percentile of the national distribution, with the national average IR, the nationwide impact increased to 30.8 million cases and $26.2 billion prevented. As done in previous vaccine impact studies [1, 22, 23] , we based our impact model on comparing measles incidence rates before and after vaccine introduction, assuming that all other factors remained unchanged before and after vaccine introduction. Other factors, such as better health care or reducing birth rates, have likely contributed to the decline of infectious diseases, but a lack of detailed information about such factors has limited the possibility of disentangling the impact of vaccination from other factors. Recent studies using mathematical modeling of national-level data have started to disentangle the effect of demographic changes and vaccination on the decline of measles, showing that almost half of the decline in measles incidence in high-income countries could be explained by the reduction in fertility rates [32, 33] . Future studies should be able to disentangle vaccination from demographic and other effects at the state and local levels as well, when detailed historical information about demographic changes and social determinants of health become available for research. Although extrapolations are difficult to make without Linear modeling, imputation with 0s Mean rates, imputation with 0s ARIMA best model, imputation with random counts Linear modeling, imputation with random counts Mean rates, imputation with random counts Figure 4 . Observed measles incidence rate and counterfactual incidence rates resulting from our default and alternative imputation and counterfactual models. All incidence rates (IRs) resulted from combining state-level rates into a national-level overview. Observed measles IRs (/100 000) and fitted values from the best autoregressive integrated moving average (ARIMA) models are shown for the prevaccination period (pre-1964) . For the vaccination period, observed values and counterfactual IRs are shown resulting from our default model and various combinations of alternative imputation and counterfactual models. The 80% confidence interval of counterfactual IRs from our default ARIMA models are shown in shaded blue.
sufficient information, even if half of the decline in measles in the United States could be attributed to demographic changes, the prevention of 15 million cases, 15 thousand deaths, and $13 billion in cost could be attributed to vaccination. The US measles vaccination program was cost saving. Other medical interventions, such as screening programs, can avoid disease, but often at a cost. For example, the breast cancer screening program is estimated to cost a net of $17 050 per life-year saved [34] , and combination antiretroviral therapy for HIV-infected patients costs $29 000 per quality-adjusted lifeyear gained [35] . Measles vaccination saved $821 per case prevented instead of costing money.
In conclusion, the substantial human impact and cost savings of measles vaccination in the United States should motivate parents and policy makers around the world to participate in, sustain, and expand vaccination programs toward measles elimination. The differences in vaccination impact across states should encourage all of us to strive for equal vaccination coverage and equal access to vaccination services throughout the United States and worldwide.
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